Ibrutinib-Associated Cardiac Tamponade with Concurrent Antiplatelet Therapy
| Autor: | John H Hughes, Jennifer L Miatech, Dillon K McCarty, M Patrick Stagg |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Side effect business.industry medicine.medical_treatment Chronic lymphocytic leukemia Case Report General Medicine medicine.disease Pericardial window chemistry.chemical_compound Anticoagulant therapy chemistry Internal medicine Cardiac tamponade Ibrutinib medicine Cardiology Platelet In patient Diseases of the blood and blood-forming organs RC633-647.5 business |
| Zdroj: | Case Reports in Hematology, Vol 2020 (2020) Case Reports in Hematology |
| ISSN: | 2090-6579 2090-6560 |
| Popis: | Ibrutinib is approved for the first-line treatment of chronic lymphocytic leukemia (CLL). A well-known side effect of ibrutinib therapy is increased bleeding risk, which ranges from mild mucocutaneous bleeding to rarely life-threatening hemorrhage. The increased bleeding tendency associated with ibrutinib is thought to be related to its effect on several platelet signaling pathways, which can be exacerbated in the setting of concurrent antiplatelet or anticoagulant therapy. We present an 82-year-old male with CLL on ibrutinib and concurrent antiplatelet therapy who developed cardiac tamponade due to a hemorrhagic pericardial effusion requiring emergent placement of a pericardial window. This case further highlights the risk of major bleeding in patients treated with ibrutinib and concurrent antiplatelet therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text